top of page

"Novel vaccination strategies against the 
three major killers"


Stefan H.E. Kaufmann (Max Planck, Berlin) Introduction to the field


 Rino Rappuoli (Novartis, Siena) Special Lecture: From inactivated microbes to synthetic vaccines


 Elena Levashina (Max Planck, Berlin) Vectors and malaria transmission


Kai Matuschewski (Max Planck, Berlin)  Basic biology in malaria


Ripley Ballou (GSK Biologicals, Belgium) Vaccine development in malaria - progress and challenges


 Anne O'Garra (MRC, London)  The Immune response in tuberculosis: from mouse models to human disease


 Willem Hanekom (University of Cape Town) Host responses induced by novel TB vaccines: lessons from clinical trials


 Robin A Weiss (University College London)  HIV: the virus and the host

Thumbi Ngund'u (KwaZulu-Natal University, Durban, S.A.)  CD8+ immune responses and immune-driven viral adaptation as a pathway to rational HIV vaccine design.


 Marita Troye-Blomberg (University of Stockholm)  How could innate and adaptive immunity be linked to improve malaria vaccine development?


 Federica Sallusto (Biomedicine Institute, Bellinzona, CH) Dissecting the human T-cell response to pathogens and vaccines


 Francesca Chiodi (Karolinska, Stockholm) Acquired B-cell immunity and vaccine development


 Ali Harandi (University of Gothenburg, Sweden)  Adjuvants and vaccine development


 January Weiner (Max Planck, Berlin)  Biomarkers and vaccine development


 Mark Cotton (Tygerberg Hospital, Cape Town) Conducting studies in infants and children in the setting of high prevalence for TB and HIV


 Anneke Hesseling (Tutu TB Centre, Cape Town) Paediatric vaccines for tuberculosis: special considerations


 Chris Wilson (Gates Foundation, Seattle)  Translating immunology into vaccinology

The course will review aspects of the immunology of Malaria, Tuberculosis, and HIV/AIDS which are important for vaccine and biomarker development, discuss how host protective immunity can translate into the design and development of novel vaccines, consider how biomarkers support vaccine development, and examine the vaccines currently under clinical trial.

The official language is English. The number of participants is limited to 75. Early registration fee is € 550.00 (until 30 June, 2013) and includes course material, lunches, coffee breaks, welcome buffet dinner and a guided tour of Roman ruins. An additional €100 will be charged for late registration.


Several bursaries are available for registration fee and/or hotel + dinners from funding provided by EFIS-EJI;  additional funding has been requested from the Bill & Melinda Gates Foundation specifically for African applicants for travel expenses, registration fee, hotel and dinners.  Final deadline for application is 30 June 2013.

The Course takes place in memory and in honour of the Ceppellini School Founder Serafino Zappacosta.

Scientific Programme

16-20 OCT

Castellammare di Stabia

(Naples) Italy

Course Directors:

Stefan H.E. Kaufmann

Max Planck Institute, Berlin


Francesca Chiodi

Karolinska Institute, Stockholm

Organizing Committee:     

S. Fontana, A. Di Giacomo, T. Reynolds 

bottom of page